FDA approval: Linagliptin

AI Summary

This is a regulatory approval record for a generic formulation of linagliptin (5 mg tablet) submitted by Teva Pharmaceuticals, approved by the FDA on 27 May 2026. The record itself does not contain clinical trial results, efficacy data, or comparative evidence; it documents only the authorization action.

Plain-language summary

This is an FDA approval action for a generic linagliptin formulation; it documents regulatory authorization but does not contain clinical trial data or efficacy evidence.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This approval permits marketing of a generic linagliptin tablet in the US. Clinicians should note that this is a regulatory authorization record and does not provide new clinical efficacy or safety data; approval implies bioequivalence to the reference product, but efficacy evidence derives from the original drug's clinical program.

Caveats

• This record does not contain clinical trial results, efficacy outcomes, or safety data.
• No comparator data, control arm, or comparative effectiveness information is reported.
• Approval of an ANDA indicates bioequivalence, not clinical superiority or new indications.
• No patient population, sample size, or follow-up duration is provided.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.